ID

29847

Description

A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00675545

Link

https://clinicaltrials.gov/show/NCT00675545

Keywords

Versions (1)
  1. 4/24/18 4/24/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

April 24, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hormone-Refractory Prostate Cancer NCT00675545

English

Eligibility Hormone-Refractory Prostate Cancer NCT00675545

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histologically confirmed adenocarcinoma of the prostate.
Description

Adenocarcinoma of prostate

Data type

boolean

Alias
UMLS CUI [1]
C0007112
2. at the time of enrollment, patients must have evidence of metastatic disease, with either measurable disease per recist criteria or non- measurable disease (i.e. positive bones scan) and psa > 5 ng/mm3.
Description

Neoplasm Metastasis | Measurable Disease | Disease Non-Measurable | Bone scan Positive | Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2]
C1513041
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C1518373
UMLS CUI [4,1]
C0203668
UMLS CUI [4,2]
C1514241
UMLS CUI [5]
C0201544
3. disease progression following androgen deprivation therapy.
Description

Disease Progression Post Antiandrogen therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0242656
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0279492
4. progression is defined according to the psa working group criteria (see 6.1.3 and 6.3).
Description

Disease Progression Definition

Data type

boolean

Alias
UMLS CUI [1,1]
C0242656
UMLS CUI [1,2]
C1704788
5. serum testosterone levels < 50 ng/mm3 (unless surgically castrate). patients must continue androgen deprivation with an lhrh analogue if they have not undergone orchiectomy.
Description

Serum testosterone measurement | Exception Castration | Androgen suppression | LHRH Analogue | Orchiectomy Absent

Data type

boolean

Alias
UMLS CUI [1]
C0428413
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007347
UMLS CUI [3]
C1515985
UMLS CUI [4,1]
C0023610
UMLS CUI [4,2]
C0243071
UMLS CUI [5,1]
C0029189
UMLS CUI [5,2]
C0332197
6. no use of an antiandrogen for at least 4 weeks.
Description

Androgen Antagonists Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C0002842
UMLS CUI [1,2]
C0332197
7. have not been treated with chemotherapy before.
Description

Prior Chemotherapy Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0332197
8. ecog performance status of <= 2.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
9. laboratory criteria for entry:
Description

Laboratory criteria

Data type

boolean

Alias
UMLS CUI [1,1]
C0022877
UMLS CUI [1,2]
C0243161
white blood cell (wbc) => 3000/mm3
Description

White Blood Cell Count procedure

Data type

boolean

Alias
UMLS CUI [1]
C0023508
platelets => 100,000/mm3
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
ast < 2.5 x upper limit of normal
Description

Aspartate aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201899
calculated cct of => 40 ml/min
Description

Other Coding

Data type

boolean

Alias
UMLS CUI [1]
C3846158
10. signed informed consent form.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
11. age: 30 years old and above
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. significant peripheral neuropathy defined as grade 2 or higher.
Description

Peripheral Neuropathy CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
2. within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium).
Description

Teleradiotherapy | Radiopharmaceutical therapy | Strontium | Samarium

Data type

boolean

Alias
UMLS CUI [1]
C0419095
UMLS CUI [2]
C2094663
UMLS CUI [3]
C0038467
UMLS CUI [4]
C0036147
3. concomitant chemotherapy or investigational agents.
Description

Chemotherapy | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0013230
Back to the top of the page

Similar models

Eligibility Hormone-Refractory Prostate Cancer NCT00675545

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
1. histologically confirmed adenocarcinoma of the prostate.
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis | Measurable Disease | Disease Non-Measurable | Bone scan Positive | Prostate specific antigen measurement
Item
2. at the time of enrollment, patients must have evidence of metastatic disease, with either measurable disease per recist criteria or non- measurable disease (i.e. positive bones scan) and psa > 5 ng/mm3.
boolean
C0027627 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
C0012634 (UMLS CUI [3,1])
C1518373 (UMLS CUI [3,2])
C0203668 (UMLS CUI [4,1])
C1514241 (UMLS CUI [4,2])
C0201544 (UMLS CUI [5])
Disease Progression Post Antiandrogen therapy
Item
3. disease progression following androgen deprivation therapy.
boolean
C0242656 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0279492 (UMLS CUI [1,3])
Disease Progression Definition
Item
4. progression is defined according to the psa working group criteria (see 6.1.3 and 6.3).
boolean
C0242656 (UMLS CUI [1,1])
C1704788 (UMLS CUI [1,2])
Serum testosterone measurement | Exception Castration | Androgen suppression | LHRH Analogue | Orchiectomy Absent
Item
5. serum testosterone levels < 50 ng/mm3 (unless surgically castrate). patients must continue androgen deprivation with an lhrh analogue if they have not undergone orchiectomy.
boolean
C0428413 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007347 (UMLS CUI [2,2])
C1515985 (UMLS CUI [3])
C0023610 (UMLS CUI [4,1])
C0243071 (UMLS CUI [4,2])
C0029189 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Androgen Antagonists Absent
Item
6. no use of an antiandrogen for at least 4 weeks.
boolean
C0002842 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Prior Chemotherapy Absent
Item
7. have not been treated with chemotherapy before.
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
ECOG performance status
Item
8. ecog performance status of <= 2.
boolean
C1520224 (UMLS CUI [1])
Laboratory criteria
Item
9. laboratory criteria for entry:
boolean
C0022877 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
White Blood Cell Count procedure
Item
white blood cell (wbc) => 3000/mm3
boolean
C0023508 (UMLS CUI [1])
Platelet Count measurement
Item
platelets => 100,000/mm3
boolean
C0032181 (UMLS CUI [1])
Aspartate aminotransferase measurement
Item
ast < 2.5 x upper limit of normal
boolean
C0201899 (UMLS CUI [1])
Other Coding
Item
calculated cct of => 40 ml/min
boolean
C3846158 (UMLS CUI [1])
Informed Consent
Item
10. signed informed consent form.
boolean
C0021430 (UMLS CUI [1])
Age
Item
11. age: 30 years old and above
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Peripheral Neuropathy CTCAE Grades
Item
1. significant peripheral neuropathy defined as grade 2 or higher.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Teleradiotherapy | Radiopharmaceutical therapy | Strontium | Samarium
Item
2. within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium).
boolean
C0419095 (UMLS CUI [1])
C2094663 (UMLS CUI [2])
C0038467 (UMLS CUI [3])
C0036147 (UMLS CUI [4])
Chemotherapy | Investigational New Drugs
Item
3. concomitant chemotherapy or investigational agents.
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial